Dateline City:
WHITEHOUSE STATION, N.J.
First Presentation of Findings in Gastric and Bladder (Urothelial Tract) Cancers
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the presentation of data from ongoing clinical trials
evaluating the anti-tumor activity of pembrolizumab, the companys
investigational anti-PD-1 antibody, at the European Society of Medical
Oncology (ESMO) 2014 in Madrid, Spain, September 26 30.
Language:
English
Contact:
MerckMedia Contacts:Ian McConnell, 908-423-3046Claire Mulhearn, 908-423-7425Investor Contacts:Joseph Romanelli, 908-423-5185Justin Holko 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more